ClinicalTrials.gg
CompletedNCT00077753Updated Jan 11, 2011

EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization

A Phase 4 interventional study of enoxaparin sodium in Venous Thromboembolism, sponsored by Sanofi. Completed at 20 sites in 20 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2011-01-11.

Sponsored by Sanofi · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
4,726
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies in Venous Thromboembolism by Sanofi — none open to participants now, none under way, none of them phase 3. Venous Thromboembolism · Sanofi.

Enrollment
Largest of 11
4,726 · median 1,090
Started
2002
the only one that year
Phase 4
Only one
of the 13
Registered
1st of 13
by date

Among the 13 studies in Venous Thromboembolism by Sanofi, this one has the largest enrollment of the 11 interventional ones that give a count, is the only one that started in 2002, is the only one in phase 4, and was the 1st registered.

Venous Thromboembolism

713 studies on the registry are indexed under Venous Thromboembolism; 147 are open to participants now.

Browse Venous Thromboembolism studies →

Open to participants now

None of the 13 studies in Venous Thromboembolism by Sanofi is open now. The open studies under Venous Thromboembolism, anywhere →

Who these studies take

Of the 113 Venous Thromboembolism studies recruiting now, 90 (80%) set no upper age limit and 13 (12%) stop at 75 or younger; 9 take children under 18; 10 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies in Venous Thromboembolism by Sanofi as a file.
02

Study summary

Primary objective:

  • To demonstrate the superiority of extended VTE prophylaxis with enoxaparin 40mg sc qd for 28 ± 4 days, compared to placebo, both following 10 ± 4 days of initial treatment with enoxaparin 40mg sc qd

Secondary objectives:

  • To assess the reduction in mortality rate at the end of the double-blind treatment period, at 3 (90 ± 10 days) and at 6 (180 ± 10 days) months from the time of entry to the study, in patients on extended prophylaxis
  • To assess the incidence of VTE at 3 months (90 ± 10 days) from the time of randomization to the study
  • To evaluate the safety of extended enoxaparin VTE prophylaxis in acutely ill medical patients with prolonged immobilization. Safety evaluation includes:

    • Major and minor hemorrhage
    • Heparin induced thrombocytopenia
    • Serious adverse events
  • To assess differences in levels of health-care utilization and cost between patients receiving extended VTE prophylaxis versus those receiving placebo.
03

Conditions studied

  • Venous Thromboembolism
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Recent immobilization ≤ 3 days
  • Level 1 mobility patients who are ≥ 40 years of age with acute medical illness or acute exacerbation of chronic medical illness
  • Level 2 mobility patients who

    • are >75 yrs of age
    • are ≥ 40 years of age and have a history of VTE (deep venous thrombosis or pulmonary embolism)
    • are ≥ 40 years of age and have a baseline diagnosis of cancer (active cancer or history of cancer)

Anticipated decreased level of mobility of 5 ± 2 days with a level of activity 1 and 2 at the time of study entry and likely to continue at a lower than pre-morbid activity level after the initial 5 ± 2 day period. PATIENTS DO NOT HAVE TO BE HOSPITALIZED IN ORDER TO BE INCLUDED IN THE STUDY.(Definition of decreased level of mobility: _Level 1:bed rest or sedentary patients _Level 2:level 1 with bathroom privileges)

  • Presence of at least one of the following medical conditions:

    • Heart Failure, class III and IV

      • Class III : Patients with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary physical activity causes fatigue, palpitationdyspnea, or anginal pain.
      • Class IV : Patients with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of the anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.
    • Acute respiratory insufficiency
    • Other acute medical conditions such as:

      • Acute ischemic stroke, any territory, with an appropriate neuroradiologic (head CT scan or brain MRI scan) providing results consistent with non hemorrhagic stroke
      • acute infection without septic shock
      • acute rheumatic disorders
      • active episode of inflammatory bowel disease
      • active cancer defined as history of or cytologically confirmed cancer in patients who are not candidates for debulking or curative intent surgery at study entry
      • Any other acute medical illness or exacerbation of chronic medical illness resulting in reduction in mobility as compared to premorbid level.

Exclusion criteria

Exclusion criteria:

  • Women who are breastfeeding, pregnant or of childbearing age and not using medically acceptable effective
  • Patients with any evidence of an active bleeding disorder
  • to anticoagulation
  • Major surgery within the previous 3 months
  • Patients who have had spinal or epidural analgesia or lumbar puncture within the preceding 24 hours
  • Known to heparin, or LMWH, or pork derived products
  • A documented previous episode of heparin-induced or LMWH induced thrombocytopenia and/or thrombosis (HIT, HAT, or HITTS)
  • Patients who have taken part in another clinical trial within the previous thirty days
  • Patients with a persistent renal failure. The patient's creatinine level must be less than the creatinine level per gender/age/weight. This will replace the calculated
  • Known or suspected severe anemia of unexplained cause considered by investigator
  • Patients with prosthetic heart valves
  • Patients with known cerebral
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
4,726 participants

Interventions

06

What researchers measure

Primary outcomes

  1. During double blind treatment : Cumulative occurrence of VTE assessed by ultrasound for all patients at 28±4 days after randomization (or earlier if symptomatic VTE) and/or V/Q lung scan for symptomatic patients ; Major hemorrhagic complications.

Secondary outcomes

  1. Occurrence of VTE between Day 1 and Day 90±10, Mortality at the end of Double-Blind Treatment, at 3 and 6 months

  2. Minor plus major hemorrhagic complications during Double-Blind Treatment.

07

Study locations

20 sites
  • Sanofi-Aventis
    Bridgewater, New Jersey, United States
  • Sanofi-Aventis
    Buenos Aires, Argentina
  • Sanofi-Aventis
    North Ryde, Australia
  • Sanofi-Aventis
    Vienna, Austria
  • Sanofi-Aventis
    Brussels, Belgium
  • Sanofi-Aventis
    Sao Paulo, Brazil
  • Sanofi-Aventis
    Laval, Canada
  • Sanofi-Aventis
    Bogota, Colombia
  • Sanofi-Aventis
    Paris, France
  • Sanofi-Aventis
    Berlin, Germany
  • Sanofi-Aventis
    Mumbai, India
  • Sanofi-Aventis
    Natanya, Israel
  • Sanofi-Aventis
    Milan, Italy
  • Sanofi-Aventis
    Mexico, Mexico
  • Sanofi-Aventis
    Warsaw, Poland
  • Sanofi-Aventis
    Moscow, Russian Federation
  • Sanofi-Aventis
    Johannesburg, South Africa
  • Sanofi-Aventis
    Barcelona, Spain
  • Sanofi-Aventis
    Megrine, Tunisia
  • Sanofi-Aventis
    Guildford, United Kingdom
08

References and documents

Publications

  • Chi G, Goldhaber SZ, Kittelson JM, Turpie AGG, Hernandez AF, Hull RD, Gold A, Curnutte JT, Cohen AT, Harrington RA, Gibson CM. Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis. J Thromb Haemost. 2017 Oct;15(10):1913-1922. doi: 10.1111/jth.13783. Epub 2017 Sep 4. PubMed 28762617 ↗
  • Turpie AG, Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Chen M, Yusen RD; EXCLAIM Investigators. Venous thromboembolism risk in ischemic stroke patients receiving extended-duration enoxaparin prophylaxis: results from the EXCLAIM study. Stroke. 2013 Jan;44(1):249-51. doi: 10.1161/STROKEAHA.112.659797. Epub 2012 Nov 1. PubMed 23117723 ↗
  • Sharma A, Chatterjee S, Lichstein E, Mukherjee D. Extended thromboprophylaxis for medically ill patients with decreased mobility: does it improve outcomes? J Thromb Haemost. 2012 Oct;10(10):2053-60. doi: 10.1111/j.1538-7836.2012.04874.x. PubMed 22863355 ↗
  • Hull RD, Schellong SM, Tapson VF, Monreal M, Samama MM, Nicol P, Vicaut E, Turpie AG, Yusen RD; EXCLAIM (Extended Prophylaxis for Venous ThromboEmbolism in Acutely Ill Medical Patients With Prolonged Immobilization) study. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010 Jul 6;153(1):8-18. doi: 10.7326/0003-4819-153-1-201007060-00004. PubMed 20621900 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2002, a primary completion of Oct 2006 and a completion of Feb 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2004
First posted
Feb 16, 2004
Start
Feb 2002
Primary completionActual
Oct 2006
CompletionActual
Feb 2007
Last update
Jan 11, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00077753
Lead sponsor
Sanofi
First posted
Feb 16, 2004
Start date
Feb 2002
Primary completion
Oct 2006
Completion
Feb 2007
Last update
Jan 11, 2011

Study contacts

Luc Sagnard
study director · Sanofi
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enoxaparin sodium

Start the discussion